San Diego-based clinical-stage biopharmaceutical company Daré Bioscience, Inc. is committed to promoting women's health in the United States by identifying, developing, and marketing products. The firm focuses on therapeutic areas in contraception, menopause, sexual and vaginal health, fertility, and reproductive health. Their current products include XACIATO, a single-dose vaginal gel prescription treatment for bacterial vaginosis in female patients 12 years of age and older. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal use that treats vulvar vaginal atrophy in women with hormone-receptor positive breast cancer, and DARE-PDM1, a vaginal hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, to address dysmenorrhea. The company's products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for treating vasomotor symptoms in hormone therapy; and Sildenafil Cream, a cream formulation of sildenafil applied topically to the vulva and vagina to treat female sexual arousal disorder. Daré Bioscience's other Phase I-ready products include DARE-204 and DARE-214, which are injectable formulations of etonogestrel, a contraceptive that provides protection over 6-month and 12-month periods, respectively. DARE-FRT1, an intravaginal ring containing bio-identical progesterone, provides broader luteal phase support as part of an in-vitro fertilization treatment, while DARE-PTB1, another intravaginal ring also containing bio-identical progesterone, aims to prevent preterm birth. The company's current pre-clinical stage products include DARE-LARC1, a contraceptive implant delivering levonorgestrel, and DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate. Daré Bioscience's DARE-LBT is a novel hydrogel formulation for the vaginal delivery of live biotherapeutics to support vaginal health, while DARE-RH1 is a non-hormonal contraception product for men and women. Daré Bioscience has licensed XACIATO in agreements with Organon & Co. and Organon International GmbH in its efforts to commercialize the product.
Daré Bioscience's ticker is DARE
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 11-50 employees working at Daré Bioscience
It is darebioscience.com
Daré Bioscience is in the Healthcare sector
Daré Bioscience is in the Biotechnology industry
The following five companies are Daré Bioscience's industry peers: